文献速递眼底病与葡萄膜炎

硫化氢:糖尿病视网膜病变发展中的潜在治疗靶点

Hydrogen Sulfide: A Potential Therapeutic Target in the Development of Diabetic Retinopathy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2020-01-01

该研究在链脲佐菌素诱导的糖尿病小鼠中给予缓释硫化氢供体GYY4137六个月,发现其可改善硫化氢水平下降、阻止糖尿病视网膜病变组织病理学特征的发展,并减轻氧化应激、MMP-9激活和线粒体损伤。分离的视网膜内皮细胞高糖培养结果与动物实验一致。结论提示补充硫化氢供体可通过减轻氧化应激和保持线粒体完整性来预防糖尿病视网膜病变。

要点

  • 缓释H2S供体GYY4137可阻止糖尿病小鼠视网膜病变组织病理学特征的发展。
  • GYY4137减轻糖尿病诱导的氧化应激、MMP-9激活和线粒体损伤。
  • 视网膜内皮细胞高糖培养结果验证了动物实验发现。

核心结论

  • 补充硫化氢供体通过减轻氧化应激和保持线粒体完整性来预防糖尿病视网膜病变的发展。
  • 硫化氢供体可能为抑制糖尿病视网膜病变发展提供新的治疗策略。

研究设计与样本

  • 链脲佐菌素诱导的糖尿病小鼠接受缓释硫化氢供体GYY4137治疗六个月,检测视网膜硫化氢水平、视网膜血管组织病理学、氧化应激、MMP-9及线粒体完整性。
  • 分离的视网膜内皮细胞在高糖培养基中加入GYY4137进行验证。

主要发现

  • 给予GYY4137改善糖尿病小鼠硫化氢水平下降,并阻止糖尿病视网膜病变组织病理学特征的发展。
  • GYY4137减弱糖尿病诱导的氧化应激增加、MMP-9激活和线粒体损伤。
  • 分离视网膜内皮细胞的结果证实了糖尿病小鼠中的发现。

临床怎么用

  • 硫化氢供体可能作为抑制糖尿病视网膜病变发展的新型治疗策略,但尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hyperglycemia damages the retinal mitochondria, and the mitochondrial damage plays a central role in the development of diabetic retinopathy. Patients with diabetes also have higher homocysteine levels, and abnormalities in homocysteine metabolism result in decreased levels of hydrogen sulfide (H2S), an endogenous gasotransmitter signaling molecule with antioxidant properties. This study aimed to investigate the role of H2S in the development of diabetic retinopathy. METHODS: Streptozotocin-induced diabetic mice were administered a slow releasing H2S donor GYY4137 for 6 months. The retina was used to measure H2S levels, and their retinal vasculature was analyzed for the histopathology characteristic of diabetic retinopathy and oxidative stress, mitochondrial damaging matrix metalloproteinase-9 (MMP-9), and mitochondrial integrity. These parameters were also measured in the isolated retinal endothelial cells incubated in high glucose medium containing GYY4137. RESULTS: Administration of GYY4137 to diabetic mice ameliorated decrease in H2S and prevented the development of histopathology, characteristic of diabetic retinopathy. Diabetes-induced increase in oxidative stress, MMP-9 activation, and mitochondrial damage were also attenuated in mice receiving GYY4137. Results from isolated retinal endothelial cells confirmed the results obtained from diabetic mice. CONCLUSIONS: Thus, supplementation of H2S donor prevents the development of diabetic retinopathy by ameliorating increase in oxidative stress and preserving the mitochondrial integrity. H2S donors may provide a novel therapeutic strategy to inhibit the development of diabetic retinopathy.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Mohammad G, Radhakrishnan R, Kowluru RA, et al. Hydrogen Sulfide: A Potential Therapeutic Target in the Development of Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2020. PMID: 33372981. doi:10.1167/iovs.61.14.35

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。